Tenaya Therapeutics (NASDAQ:TNYA) Rating Reiterated by Canaccord Genuity Group

Tenaya Therapeutics (NASDAQ:TNYA)‘s stock had its “buy” rating reiterated by research analysts at Canaccord Genuity Group in a report released on Friday, Benzinga reports. They currently have a $16.00 target price on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a report on Friday. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tenaya Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $15.25.

Tenaya Therapeutics Trading Down 5.1 %

Shares of TNYA opened at $2.04 on Friday. Tenaya Therapeutics has a twelve month low of $1.61 and a twelve month high of $7.01. The firm has a market capitalization of $160.18 million, a P/E ratio of -1.24 and a beta of 2.35. The firm’s 50-day moving average is $2.27 and its two-hundred day moving average is $3.29.

Tenaya Therapeutics (NASDAQ:TNYA) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. Analysts predict that Tenaya Therapeutics will post -1.52 EPS for the current year.

Insider Buying and Selling

In other Tenaya Therapeutics news, CEO Faraz Ali sold 9,748 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $2.89, for a total transaction of $28,171.72. Following the sale, the chief executive officer now owns 188,331 shares in the company, valued at approximately $544,276.59. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 19,539 shares of company stock worth $56,468 in the last ninety days. Insiders own 32.76% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in TNYA. Vanguard Group Inc. grew its holdings in shares of Tenaya Therapeutics by 16.4% during the first quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company’s stock worth $14,973,000 after buying an additional 403,472 shares in the last quarter. HighPoint Advisor Group LLC purchased a new stake in Tenaya Therapeutics in the 4th quarter worth approximately $228,000. American Century Companies Inc. raised its holdings in Tenaya Therapeutics by 27.7% in the 2nd quarter. American Century Companies Inc. now owns 102,114 shares of the company’s stock valued at $317,000 after acquiring an additional 22,146 shares during the last quarter. Integral Health Asset Management LLC raised its holdings in Tenaya Therapeutics by 3.3% in the 2nd quarter. Integral Health Asset Management LLC now owns 2,325,000 shares of the company’s stock valued at $7,208,000 after acquiring an additional 75,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Tenaya Therapeutics by 42.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 102,026 shares of the company’s stock worth $316,000 after purchasing an additional 30,446 shares during the period. Institutional investors and hedge funds own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.